Significant Progress Achieved in the First Two Months of CY25

Echo IQ (ASX: EIQ) has made significant progress in its commercialisation strategy, particularly with the integration and uptake of EchoSolv-AS in the US. The AI-powered cardiac screening tool is now actively used at Beth Israel Deaconess Medical Centre, a flagship site affiliated with Harvard Medical School. A study is underway to explore the health and economic benefits of early intervention. Additionally, four other US hospitals are using EchoSolv-AS, with over 60 more earmarked for integration in the coming months.

The company is advancing its reimbursement strategy. In May 2025, it will present to the Centers for Medicare & Medicaid Services (CMS) to support the receipt of a Category III CPT code, a key step toward insurance reimbursement. Echo IQ is also preparing for a planned listing on the OTCQB market to enhance US investor engagement.

Echo IQ has appointed Sam Dribin as its Chief Technology Officer, further strengthening its US expansion. With over 20 years of experience in software, AI, and medical devices, he will oversee product development and integration efforts. The company remains focused on partnerships, R&D, and scaling its commercial footprint.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com